<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Dermatologic and ocular manifestations of inflammatory bowel disease</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Dermatologic and ocular manifestations of inflammatory bowel disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Dermatologic and ocular manifestations of inflammatory bowel disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mark A Peppercorn, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Adam S Cheifetz, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer E Thorne, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sunanda V Kane, MD, MSPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen M Robson, MD, MBA, FACG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 30, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>There are several extraintestinal manifestations of inflammatory bowel disease (IBD). These manifestations vary in severity and can be more debilitating than the underlying IBD. While some extraintestinal manifestations parallel the disease activity of IBD (eg, erythema nodosum, episcleritis, and Sweet syndrome), the course of others (eg, pyoderma gangrenosum, uveitis) is independent of intestinal inflammation.</p><p>This topic will review the skin and eye manifestations of IBD. The clinical manifestations, diagnosis, and management of ulcerative colitis and Crohn disease are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4067.html" rel="external">"Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/4051.html" rel="external">"Medical management of low-risk adult patients with mild to moderate ulcerative colitis"</a> and  <a class="medical medical_review" href="/z/d/html/4068.html" rel="external">"Management of the hospitalized adult patient with severe ulcerative colitis"</a> and  <a class="medical medical_review" href="/z/d/html/4070.html" rel="external">"Clinical manifestations, diagnosis, and prognosis of Crohn disease in adults"</a> and  <a class="medical medical_review" href="/z/d/html/4069.html" rel="external">"Overview of the medical management of mild (low risk) Crohn disease in adults"</a> and  <a class="medical medical_review" href="/z/d/html/16224.html" rel="external">"Medical management of moderate to severe Crohn disease in adults"</a>.)</p><p class="headingAnchor" id="H518779762"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The prevalence of extraintestinal manifestations in patients with IBD has not been extensively studied. However, data suggest that 6 to 40 percent of patients with IBD have one or more extraintestinal manifestation [<a href="#rid1">1-3</a>]. Up to 15 percent of patients have a cutaneous manifestation of IBD [<a href="#rid4">4,5</a>]. Ocular manifestations of IBD occur in 4 to 10 percent of patients and may be more likely to occur in patients with Crohn disease as compared with ulcerative colitis [<a href="#rid6">6,7</a>].</p><p class="headingAnchor" id="H2"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The pathogenesis of extraintestinal manifestations in patients with IBD is incompletely understood. However, it is hypothesized that the diseased gastrointestinal mucosa may trigger an immune response at the extraintestinal site due to shared epitopes [<a href="#rid8">8</a>]. Triggers of the immune response in certain organs may be influenced by genetic factors. Associations of extraintestinal manifestations of IBD with major histocompatibility complex loci have also been demonstrated [<a href="#rid9">9</a>]. As an example, HLA-B27 and HLA-B58 are associated with ocular inflammation in patients with IBD.</p><p class="headingAnchor" id="H3"><span class="h1">DERMATOLOGIC DISEASE</span></p><p class="headingAnchor" id="H4"><span class="h2">Erythema nodosum</span><span class="headingEndMark"> — </span>Erythema nodosum is the most common dermatologic manifestation of inflammatory bowel disease (IBD), occurring in up to 3 percent of patients with ulcerative colitis and up to 8 percent of patients with Crohn disease [<a href="#rid10">10-12</a>]. Lesions typically consist of raised, tender, red or violet subcutaneous nodules that are 1 to 5 cm in diameter (<a class="graphic graphic_picture graphicRef80056" href="/z/d/graphic/80056.html" rel="external">picture 1</a>). The nodules are most commonly located on the extensor surfaces of the extremities, particularly over the anterior tibial area. Biopsy of these lesions shows focal panniculitis. However, the diagnosis is most often clinical, and biopsy is required only in atypical cases (eg, patients with no lesions on the legs, persistence beyond six to eight weeks, or the development of ulceration). </p><p>The appearance of erythema nodosum usually parallels intestinal disease activity, and treatment directed at the underlying IBD usually results in resolution of the lesions. Skin lesions rarely precede the onset of IBD, or occur during quiescent phases of IBD; in these settings, therapy with other treatments, including <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>, may be required. The management of erythema nodosum is discussed separately. </p><p class="headingAnchor" id="H5"><span class="h2">Pyoderma gangrenosum</span><span class="headingEndMark"> — </span>Pyoderma gangrenosum is the second most common dermatologic manifestation of IBD. However, the proportion of patients with IBD who develop pyoderma gangrenosum appears to be small [<a href="#rid10">10,13</a>]. In one cohort study that included 2402 patients with IBD, pyoderma gangrenosum was detected in only 0.75 percent of patients [<a href="#rid10">10</a>].</p><p>The lesions initially appear as single or multiple erythematous papules or pustules that are often preceded by trauma to the skin (<a class="graphic graphic_picture graphicRef53733" href="/z/d/graphic/53733.html" rel="external">picture 2</a>). They occur most commonly on the legs, but can develop in any area of the body, including the abdominal wall adjacent to the stoma after colectomy or surgical scars [<a href="#rid14">14</a>]. Subsequent necrosis of the dermis leads to the development of deep ulcerations that contain purulent material that is usually sterile on culture (<a class="graphic graphic_picture graphicRef52528" href="/z/d/graphic/52528.html" rel="external">picture 3</a>). Biopsy reveals nonspecific findings consistent with a sterile abscess (<a class="graphic graphic_picture graphicRef59489" href="/z/d/graphic/59489.html" rel="external">picture 4</a>). (See  <a class="medical medical_review" href="/z/d/html/13782.html" rel="external">"Pyoderma gangrenosum: Pathogenesis, clinical features, and diagnosis", section on 'Clinical manifestations'</a>.)</p><p>Pyoderma gangrenosum lesions usually do not parallel IBD activity [<a href="#rid15">15</a>]. In patients with active IBD and pyoderma gangrenosum, therapy with systemic glucocorticoids usually results in healing. Pyoderma gangrenosum is also responsive to tumor necrosis factor (TNF) antagonists [<a href="#rid16">16</a>]. The clinical manifestations, diagnosis, and management of pyoderma gangrenosum are discussed in detail, separately. (See  <a class="medical medical_review" href="/z/d/html/83623.html" rel="external">"Pyoderma gangrenosum: Treatment and prognosis", section on 'Treatment principles'</a> and  <a class="medical medical_review" href="/z/d/html/4069.html" rel="external">"Overview of the medical management of mild (low risk) Crohn disease in adults"</a> and  <a class="medical medical_review" href="/z/d/html/16224.html" rel="external">"Medical management of moderate to severe Crohn disease in adults"</a>.)</p><p class="headingAnchor" id="H3269416662"><span class="h2">Hidradenitis suppurativa</span><span class="headingEndMark"> — </span>Hidradenitis suppurativa (HS) is a chronic follicular occlusive disease involving the follicular portion of the folliculopilosebaceous units (FPSUs) (<a class="graphic graphic_picture graphicRef114609" href="/z/d/graphic/114609.html" rel="external">picture 5</a>). Data have suggested an association between HS and IBD, particularly in patients with Crohn disease [<a href="#rid17">17,18</a>]. The diagnosis and management of HS are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5575.html" rel="external">"Hidradenitis suppurativa: Pathogenesis, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/7605.html" rel="external">"Hidradenitis suppurativa: Management"</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Rare dermatologic diseases</span></p><p class="headingAnchor" id="H112316505"><span class="h3">Neutrophilic dermatoses</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sweet syndrome</strong> – Sweet syndrome is an acute inflammatory dermatitis characterized by tender papules, plaques, and nodules distributed on the face, arms, and trunk (<a class="graphic graphic_picture graphicRef74393" href="/z/d/graphic/74393.html" rel="external">picture 6</a>). Skin lesions are most commonly seen on the head, neck, and upper extremities. Episcleritis is a frequent ocular finding. Sweet syndrome is usually associated with active IBD, but may precede the onset of intestinal symptoms in approximately 20 percent of patients [<a href="#rid19">19</a>]. Biopsy of the lesion reveals an intense neutrophilic infiltrate without evidence of vasculitis. The lesions of Sweet syndrome usually respond quickly to oral glucocorticoids [<a href="#rid20">20</a>]. The clinical manifestations, diagnosis, and management of Sweet syndrome are discussed in detail, separately. (See  <a class="medical medical_review" href="/z/d/html/13784.html" rel="external">"Sweet syndrome (acute febrile neutrophilic dermatosis): Pathogenesis, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/86567.html" rel="external">"Sweet syndrome (acute febrile neutrophilic dermatosis): Management and prognosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aseptic abscess syndrome</strong> – In rare cases, patients with IBD may present with aseptic abscess syndrome. The typical presentation includes fever, weight loss, abdominal pain, and leukocytosis [<a href="#rid21">21</a>]. Patients characteristically have aseptic sterile collections with a neutrophil predominant infiltrate. These sterile abscesses are usually located in the spleen, but approximately 20 percent of patients have cutaneous abscesses. Both systemic glucocorticoids and TNF antagonists have been effective in treating aseptic abscess syndrome in small observational studies [<a href="#rid22">22</a>]. However, the disease frequently follows a relapsing course.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bowel-associated dermatosis-arthritis syndrome</strong> – Patients with bowel-associated dermatosis-arthritis syndrome present with a serum sickness-like syndrome characterized by fever, chills, malaise, arthralgia, arthritis, and myalgia, which frequently precede the skin eruption [<a href="#rid23">23</a>]. Patients may have associated diarrhea due to active inflammation from underlying IBD. The aseptic non-erosive polyarthritis is asymmetric, episodic, and affects both small and large joints. The most characteristic cutaneous skin lesions are erythematous macules up to 1 cm in diameter that develop a central papulovesicle or pustule (<a class="graphic graphic_picture graphicRef98997" href="/z/d/graphic/98997.html" rel="external">picture 7</a>). The eruption most often occurs on the upper extremities and trunk. Treatment consists of management of the underlying IBD with glucocorticoids. In refractory cases, other immunosuppressive agents, such as <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> or TNF antagonists, may be required. The clinical manifestations, diagnosis, and management of bowel-associated dermatosis-arthritis syndrome are discussed in detail, separately. (See  <a class="medical medical_review" href="/z/d/html/5571.html" rel="external">"Neutrophilic dermatoses", section on 'Bowel-associated dermatosis-arthritis syndrome'</a>.)</p><p></p><p class="headingAnchor" id="H112316512"><span class="h3">Cutaneous vasculitis</span><span class="headingEndMark"> — </span>Cutaneous small vessel vasculitis and cutaneous polyarteritis nodosa (PAN) are associated with IBD [<a href="#rid24">24,25</a>]. The major clinical findings in patients with cutaneous vasculitis include nonblanching palpable purpura and/or petechiae (<a class="graphic graphic_picture graphicRef94489" href="/z/d/graphic/94489.html" rel="external">picture 8</a>). Sometimes these lesions coalesce, ulcerate, or are surrounded by hemorrhagic bullae. Skin manifestations of PAN may include tender erythematous nodules, purpura, livedo reticularis, ulcers, and bullous or vesicular eruption. The clinical manifestations, diagnosis, and management of cutaneous vasculitis are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8241.html" rel="external">"Overview of cutaneous small vessel vasculitis", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H112316695"><span class="h3">Metastatic Crohn disease</span><span class="headingEndMark"> — </span>Metastatic Crohn disease is characterized by cutaneous ulcerating nodules and violaceous plaques that demonstrate histologic similarity to the underlying Crohn disease and have noncaseating granulomas on biopsy (<a class="graphic graphic_picture graphicRef103584" href="/z/d/graphic/103584.html" rel="external">picture 9</a>). These lesions can occur anywhere on the body, but most often occur on the anterior abdominal wall in the submammary area, intertriginous skin, and on the extremities [<a href="#rid26">26,27</a>]. Observational studies suggest that lesions respond to treatment of the underlying Crohn disease [<a href="#rid28">28,29</a>]. The management of Crohn disease is discussed in detail, separately. (See  <a class="medical medical_review" href="/z/d/html/4069.html" rel="external">"Overview of the medical management of mild (low risk) Crohn disease in adults"</a> and  <a class="medical medical_review" href="/z/d/html/16224.html" rel="external">"Medical management of moderate to severe Crohn disease in adults"</a>.)</p><p class="headingAnchor" id="H465075349"><span class="h3">Epidermolysis bullosa acquisita</span><span class="headingEndMark"> — </span>Epidermolysis bullosa acquisita is a rare subepithelial blistering disorder that has been associated with Crohn disease [<a href="#rid30">30,31</a>]. Classical epidermolysis bullosa acquisita presents as a mechanobullous disorder associated with skin fragility and noninflammatory tense bullae, with a predilection for acral areas (<a class="graphic graphic_picture graphicRef62505" href="/z/d/graphic/62505.html" rel="external">picture 10</a>). The onset of the gastrointestinal symptoms generally precedes or occurs simultaneously with the skin lesions [<a href="#rid30">30</a>]. The clinical manifestations, diagnosis, and management of epidermolysis bullosa acquisita are discussed in detail, separately. (See  <a class="medical medical_review" href="/z/d/html/15299.html" rel="external">"Epidermolysis bullosa acquisita"</a>.)</p><p class="headingAnchor" id="H481364736"><span class="h2">Associated conditions and complications</span><span class="headingEndMark"> — </span>Patients may also have other dermatologic diseases associated with the underlying IBD or that develop as a consequence of therapy. Dermatologic complications of TNF antagonists and glucocorticoids are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7970.html" rel="external">"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects", section on 'Cutaneous reactions'</a> and  <a class="medical medical_review" href="/z/d/html/7975.html" rel="external">"Tumor necrosis factor-alpha inhibitors: Risk of malignancy", section on 'Skin cancer risk'</a> and  <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>.)</p><p class="headingAnchor" id="H481364787"><span class="h3">Psoriasis</span><span class="headingEndMark"> — </span>Psoriasis is the most frequently associated dermatologic disease in patients with IBD [<a href="#rid32">32,33</a>]. In one study, for example, psoriasis was present in 13 of 136 (9.6 percent) patients with Crohn disease as compared with 3 of 136 (2 percent) controls [<a href="#rid33">33</a>]. In addition, patients with Crohn disease were more likely to have a first-degree relative with psoriasis (10 versus 3 percent). Chronic plaque psoriasis, the most common presentation of psoriasis, most commonly presents with sharply defined erythematous plaques with overlying silvery scales (<a class="graphic graphic_picture graphicRef87343 graphicRef54581 graphicRef87443 graphicRef87441 graphicRef99437" href="/z/d/graphic/87343.html" rel="external">picture 11A-E</a>). The scalp, extensor elbows, knees, and back are common locations for plaque psoriasis. The onset of psoriasis usually precedes IBD, and the course of psoriasis is independent of the disease activity of IBD. [<a href="#rid33">33,34</a>]. The clinical manifestations, diagnosis, and management of psoriasis are discussed in detail, separately. (See  <a class="medical medical_review" href="/z/d/html/5664.html" rel="external">"Psoriasis: Epidemiology, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults"</a>.)</p><p class="headingAnchor" id="H481364889"><span class="h3">Skin cancer</span><span class="headingEndMark"> — </span>Patients with IBD are at an increased risk for melanoma [<a href="#rid35">35</a>]. In a meta-analysis of 12 cohort studies, patients with IBD were at an increased risk of melanoma as compared with the general population (relative risk [RR] 1.37, 95% CI 1.10-1.70), with a pooled crude incidence rate of melanoma of 27.5 cases/100,000 person-years (95% CI 19.9-37.0) [<a href="#rid36">36</a>]<em>. </em>The risk was increased among patients with Crohn disease and ulcerative colitis (RR 1.80; 95% CI 1.17-2.75 and 1.23; 95% CI 1.01-1.50, respectively). This risk appeared to be independent of biologic use, which may also increase the risk of melanoma [<a href="#rid37">37</a>]. The risk of skin cancer associated with TNF antagonists is discussed in detail, separately. (See  <a class="medical medical_review" href="/z/d/html/7975.html" rel="external">"Tumor necrosis factor-alpha inhibitors: Risk of malignancy", section on 'Skin cancer risk'</a>.)</p><p>Among patients with IBD, the use of thiopurines has been associated with nonmelanoma skin cancer (NMSC) [<a href="#rid38">38</a>]. In a meta-analysis of eight studies that included 60,351 patients with IBD, the risk of NMSC was increased twofold with the use of thiopurines (hazard ratio 2.28, 95% CI 1.5-3.5) [<a href="#rid39">39</a>]. However, there was significant heterogeneity between studies included in the meta-analysis, and the risk of NMSC may be overestimated due to ascertainment bias. (See  <a class="medical medical_review" href="/z/d/html/4056.html" rel="external">"Overview of azathioprine and mercaptopurine use in inflammatory bowel disease", section on 'Malignancy'</a>.)</p><p class="headingAnchor" id="H7"><span class="h1">OCULAR DISEASE</span></p><p class="headingAnchor" id="H564074090"><span class="h2">Indications for urgent evaluation</span><span class="headingEndMark"> — </span>Several ocular diseases may be associated with inflammatory bowel disease (IBD), some of which require urgent evaluation by an ophthalmologist. (See  <a class="medical medical_review" href="/z/d/html/6900.html" rel="external">"The red eye: Evaluation and management"</a>.)</p><p>Warning signs that should prompt urgent evaluation by an ophthalmologist include:</p><p class="bulletIndent1"><span class="glyph">●</span>Reduction of visual acuity (concerns about keratitis, uveitis, angle-closure glaucoma).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severe foreign body sensation that prevents the patient from keeping the eye open (concerns about keratitis).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fixed pupil (concerns about angle-closure glaucoma). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severe headache with nausea (concerns about angle-closure glaucoma).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Corneal opacity (concerns about keratitis).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ciliary flush: a pattern of injection in which the redness is most pronounced in a ring at the limbus (the limbus is the transition zone between the cornea and the sclera) (concerns about keratitis, anterior uveitis, angle closure glaucoma).</p><p></p><p class="headingAnchor" id="H8"><span class="h2">Episcleritis</span><span class="headingEndMark"> — </span>Episcleritis, inflammation of the episclera, the layer directly beneath the conjunctiva, is the most common ocular manifestation of IBD, occurring in 2 to 5 percent of patients [<a href="#rid40">40</a>]. Episcleritis characteristically flares during increases of intestinal IBD activity.</p><p>Episcleritis should be suspected in patients with IBD who present with acute redness of one or both eyes and complaints of irritation, itching, or burning. Pain or tenderness to palpation is common. Injection of the ciliary vessels and inflammation of the episcleral tissues are the prominent features on physical examination; episcleral nodules may also be present (<a class="graphic graphic_picture graphicRef76962 graphicRef67740" href="/z/d/graphic/76962.html" rel="external">picture 12A-B</a>).</p><p>Episcleritis does not produce significant ocular complications and does not impair vision. Management consists of topical therapy to provide symptomatic relief and treatment of the underlying IBD. The clinical manifestations, diagnosis, and management of episcleritis are discussed in detail, separately. (See  <a class="medical medical_review" href="/z/d/html/5610.html" rel="external">"Episcleritis"</a>.)</p><p class="headingAnchor" id="H20475250"><span class="h2">Scleritis</span><span class="headingEndMark"> — </span>Scleritis is a severe ocular disorder that can impair vision. Scleritis is usually associated with a severe, constant, boring pain that worsens at night or in the early morning hours and radiates to the face and periorbital region. The extraocular muscles insert into the sclera, which explains why ocular movements exacerbate the pain associated with scleral inflammation. The pain generally limits activity and often prevents sleep. Additional symptoms include headache, watering of the eye, ocular redness, and photophobia. Diffuse anterior scleritis is associated with widespread ocular erythema and scleral edema (<a class="graphic graphic_picture graphicRef55397" href="/z/d/graphic/55397.html" rel="external">picture 13</a>). When posterior scleritis occurs in isolation, the eye is white. However, inflammation of parts of the posterior sclera can be seen at extremes of the patient's gaze. Scleritis does not parallel the disease activity of IBD and may precede or follow the diagnosis of IBD [<a href="#rid40">40</a>]. The clinical manifestations, diagnosis, and management of scleritis are discussed in detail, separately. (See  <a class="medical medical_review" href="/z/d/html/5599.html" rel="external">"Clinical manifestations and diagnosis of scleritis"</a> and  <a class="medical medical_review" href="/z/d/html/5598.html" rel="external">"Treatment of scleritis"</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Uveitis</span><span class="headingEndMark"> — </span>Uveitis occurs in 0.5 to 3 percent of patients with IBD. Uveitis may precede diagnosis of IBD and may be associated with an axial and/or peripheral arthritis. It is four times more common in females as compared with males. It is insidious in onset and can recur in the contralateral eye [<a href="#rid41">41</a>].</p><p>Anterior uveitis may produce pain and redness; posterior or intermediate uveitis is more likely to be painless, but is often associated with floaters and/or some degree of visual loss. The uveitis in patients with IBD more commonly involves the posterior uveal tract. The diagnosis requires slit-lamp examination and a dilated fundus examination to detect inflammation of the uveal tract. Corneal clouding and conjunctival injection may also be seen (<a class="graphic graphic_picture graphicRef75384" href="/z/d/graphic/75384.html" rel="external">picture 14</a>). (See  <a class="medical medical_review" href="/z/d/html/5581.html" rel="external">"Uveitis: Etiology, clinical manifestations, and diagnosis", section on 'Diagnosis and referral'</a>.)</p><p>The course of uveitis usually does not parallel the activity of IBD. Prompt diagnosis and therapy with topical or systemic glucocorticoids is required. An acute episode may be followed by iris atrophy, lens deposits, and synechiae. Secondary glaucoma and rarely blindness may occur if management is delayed. (See  <a class="medical medical_review" href="/z/d/html/5592.html" rel="external">"Uveitis: Treatment"</a> and  <a class="medical medical_review" href="/z/d/html/6903.html" rel="external">"Angle-closure glaucoma"</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">Rare ocular diseases</span><span class="headingEndMark"> — </span>Other eye conditions may also be seen in patients with IBD. Ocular side effects of medications used to treat IBD are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7509.html" rel="external">"Major side effects of low-dose methotrexate", section on 'Others'</a> and  <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>.)</p><p class="headingAnchor" id="H481363492"><span class="h3">Keratopathy</span><span class="headingEndMark"> — </span>Corneal disease (keratopathy) is a rare manifestation of IBD [<a href="#rid42">42,43</a>]. Patients present with eye pain or foreign body sensation. Lesions may be seen as an opacity in the peripheral cornea and can potentially thin or perforate the cornea and affect vision. Topical glucocorticoids should be avoided as they can contribute to corneal thinning. Treatment usually involves oral glucocorticoids or immunosuppressive agents.</p><p class="headingAnchor" id="H481363498"><span class="h3">Retinopathy</span><span class="headingEndMark"> — </span>Retinal vascular disease with central vein occlusion as well as retinal vasculitis involving the retinal arteries have rarely been reported in Crohn disease [<a href="#rid44">44</a>]. Central serous chorioretinopathy with bullous retinal detachment has been associated with ulcerative colitis [<a href="#rid45">45</a>].</p><p class="headingAnchor" id="H4092949793"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/109937.html" rel="external">"Society guideline links: Ulcerative colitis in adults"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/109856.html" rel="external">"Society guideline links: Crohn disease in adults"</a>.)</p><p class="headingAnchor" id="H11"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/85627.html" rel="external">"Patient education: Erythema nodosum (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/2004.html" rel="external">"Patient education: Crohn disease (Beyond the Basics)"</a>) </p><p></p><p class="headingAnchor" id="H12"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Approximately 6 to 40 percent of patients with inflammatory bowel disease (IBD) have one or more extraintestinal manifestation. Up to 8 percent of patients have a cutaneous manifestation of IBD. Ocular manifestations of IBD occur in 4 to 10 percent of patients with IBD, occurring more often in Crohn disease as compared with ulcerative colitis. While some extraintestinal manifestations parallel the disease activity of IBD (eg, erythema nodosum, episcleritis, and Sweet syndrome), the course of others (eg, pyoderma gangrenosum, uveitis) is independent of intestinal inflammation. (See <a class="local">'Introduction'</a> above and <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The pathogenesis of extraintestinal manifestations is incompletely understood. However, it is hypothesized that the diseased gastrointestinal mucosa may trigger an immune response at the extraintestinal site due to shared epitopes. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Erythema nodosum and pyoderma gangrenosum are the most common dermatologic manifestations of IBD (<a class="graphic graphic_picture graphicRef80056" href="/z/d/graphic/80056.html" rel="external">picture 1</a> and <a class="graphic graphic_picture graphicRef53733" href="/z/d/graphic/53733.html" rel="external">picture 2</a> and <a class="graphic graphic_picture graphicRef52528" href="/z/d/graphic/52528.html" rel="external">picture 3</a>). Patients with IBD also appear to be at an increased risk for melanoma. (See <a class="local">'Dermatologic disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Erythema nodosum typically appears as raised, tender, red or violet subcutaneous nodules on the extensor surfaces of extremities (<a class="graphic graphic_picture graphicRef80056" href="/z/d/graphic/80056.html" rel="external">picture 1</a>). As erythema nodosum usually parallels intestinal disease activity, treatment is directed at the underlying IBD. (See <a class="local">'Erythema nodosum'</a> above and  <a class="medical medical_review" href="/z/d/html/5612.html" rel="external">"Erythema nodosum"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pyoderma gangrenosum lesions may appear as erythematous papules or pustules that are often preceded by trauma to the skin (<a class="graphic graphic_picture graphicRef53733" href="/z/d/graphic/53733.html" rel="external">picture 2</a>). Subsequent necrosis of the dermis leads to the development of deep ulcers. Therapy directed at the underlying IBD usually results in healing. (See <a class="local">'Pyoderma gangrenosum'</a> above and  <a class="medical medical_review" href="/z/d/html/13782.html" rel="external">"Pyoderma gangrenosum: Pathogenesis, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/83623.html" rel="external">"Pyoderma gangrenosum: Treatment and prognosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Several ocular diseases may be associated with IBD, some of which require urgent evaluation by an ophthalmologist. Warning signs that should prompt urgent evaluation by an ophthalmologist include (see <a class="local">'Ocular disease'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Reduction of visual acuity </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severe foreign body sensation that prevents the patient from keeping the eye open </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Fixed pupil </p><p class="bulletIndent2"><span class="glyph">•</span>Severe headache with nausea </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Corneal opacity </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ciliary flush: a pattern of injection in which the redness is most pronounced in a ring at the limbus (the limbus is the transition zone between the cornea and the sclera) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Episcleritis should be suspected in patients with IBD who present with acute redness of one or both eyes and complaints of irritation, itching, or burning. Pain or tenderness to palpation is common. Injection of the ciliary vessels and inflammation of the episcleral tissues are the prominent features on physical examination; episcleral nodules may also be present (<a class="graphic graphic_picture graphicRef76962" href="/z/d/graphic/76962.html" rel="external">picture 12A</a> and <a class="graphic graphic_picture graphicRef67740" href="/z/d/graphic/67740.html" rel="external">picture 12B</a>). Management consists of topical therapy to provide symptomatic relief and treatment of the underlying IBD. (See <a class="local">'Episcleritis'</a> above and  <a class="medical medical_review" href="/z/d/html/5610.html" rel="external">"Episcleritis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Scleritis is usually associated with a severe, constant, boring pain that worsens at night or in the early morning hours and radiates to the face and periorbital region. Diffuse anterior scleritis is associated with widespread ocular erythema and scleral edema. When posterior scleritis occurs in isolation, the eye is white. However, inflammation of parts of the posterior sclera can be seen only at extremes of the patient's gaze. Scleritis does not parallel IBD disease activity and may precede or follow the diagnosis of IBD. Scleritis is a severe ocular disorder that can impair vision and requires prompt diagnosis and treatment by an ophthalmologist. (See <a class="local">'Scleritis'</a> above and  <a class="medical medical_review" href="/z/d/html/5599.html" rel="external">"Clinical manifestations and diagnosis of scleritis"</a> and  <a class="medical medical_review" href="/z/d/html/5598.html" rel="external">"Treatment of scleritis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anterior uveitis may produce pain and redness; posterior or intermediate uveitis is more likely to be painless, but is often associated with floaters and/or some degree of visual loss (<a class="graphic graphic_picture graphicRef75384" href="/z/d/graphic/75384.html" rel="external">picture 14</a>). Prompt diagnosis and therapy with topical or systemic glucocorticoids is required. An acute episode may be followed by iris atrophy, lens deposits, and synechiae. Secondary glaucoma and rarely blindness may occur if management is delayed. (See <a class="local">'Uveitis'</a> above and  <a class="medical medical_review" href="/z/d/html/5581.html" rel="external">"Uveitis: Etiology, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/5592.html" rel="external">"Uveitis: Treatment"</a>.)</p><p></p><p class="headingAnchor" id="H3091880682"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Paul Rutgeerts, MD (deceased), who contributed as a section editor for UpToDate in Gastroenterology.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol 2001; 96:1116.</a></li><li><a class="nounderline abstract_t">Ricart E, Panaccione R, Loftus EV Jr, et al. Autoimmune disorders and extraintestinal manifestations in first-degree familial and sporadic inflammatory bowel disease: a case-control study. Inflamm Bowel Dis 2004; 10:207.</a></li><li><a class="nounderline abstract_t">Kilic Y, Kamal S, Jaffar F, et al. Prevalence of Extraintestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Inflamm Bowel Dis 2023.</a></li><li><a class="nounderline abstract_t">Vavricka SR, Brun L, Ballabeni P, et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol 2011; 106:110.</a></li><li><a class="nounderline abstract_t">Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients. Medicine (Baltimore) 1976; 55:401.</a></li><li><a class="nounderline abstract_t">Mintz R, Feller ER, Bahr RL, Shah SA. Ocular manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2004; 10:135.</a></li><li><a class="nounderline abstract_t">Salmon JF, Wright JP, Murray AD. Ocular inflammation in Crohn's disease. Ophthalmology 1991; 98:480.</a></li><li><a class="nounderline abstract_t">Das KM, Vecchi M, Sakamaki S. A shared and unique epitope(s) on human colon, skin, and biliary epithelium detected by a monoclonal antibody. Gastroenterology 1990; 98:464.</a></li><li><a class="nounderline abstract_t">Orchard TR, Chua CN, Ahmad T, et al. Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and the role of HLA genes. Gastroenterology 2002; 123:714.</a></li><li><a class="nounderline abstract_t">Farhi D, Cosnes J, Zizi N, et al. Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: a cohort study of 2402 patients. Medicine (Baltimore) 2008; 87:281.</a></li><li><a class="nounderline abstract_t">Karmiris K, Avgerinos A, Tavernaraki A, et al. Prevalence and Characteristics of Extra-intestinal Manifestations in a Large Cohort of Greek Patients with Inflammatory Bowel Disease. J Crohns Colitis 2016; 10:429.</a></li><li><a class="nounderline abstract_t">Lakatos L, Pandur T, David G, et al. Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: results of a 25-year follow-up study. World J Gastroenterol 2003; 9:2300.</a></li><li><a class="nounderline abstract_t">Powell FC, Schroeter AL, Su WP, Perry HO. Pyoderma gangrenosum: a review of 86 patients. Q J Med 1985; 55:173.</a></li><li><a class="nounderline abstract_t">Keltz M, Lebwohl M, Bishop S. Peristomal pyoderma gangrenosum. J Am Acad Dermatol 1992; 27:360.</a></li><li><a class="nounderline abstract_t">Thornton JR, Teague RH, Low-Beer TS, Read AE. Pyoderma gangrenosum and ulcerative colitis. Gut 1980; 21:247.</a></li><li><a class="nounderline abstract_t">Agarwal A, Andrews JM. Systematic review: IBD-associated pyoderma gangrenosum in the biologic era, the response to therapy. Aliment Pharmacol Ther 2013; 38:563.</a></li><li><a class="nounderline abstract_t">Chen WT, Chi CC. Association of Hidradenitis Suppurativa With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. JAMA Dermatol 2019; 155:1022.</a></li><li><a class="nounderline abstract_t">Yadav S, Singh S, Edakkanambeth Varayil J, et al. Hidradenitis Suppurativa in Patients With Inflammatory Bowel Disease: A Population-Based Cohort Study in Olmsted County, Minnesota. Clin Gastroenterol Hepatol 2016; 14:65.</a></li><li><a class="nounderline abstract_t">Travis S, Innes N, Davies MG, et al. Sweet's syndrome: an unusual cutaneous feature of Crohn's disease or ulcerative colitis. The South West Gastroenterology Group. Eur J Gastroenterol Hepatol 1997; 9:715.</a></li><li><a class="nounderline abstract_t">Uihlein LC, Brandling-Bennett HA, Lio PA, Liang MG. Sweet syndrome in children. Pediatr Dermatol 2012; 29:38.</a></li><li><a class="nounderline abstract_t">André M, Aumaître O. [Aseptic abscesses syndrome]. Rev Med Interne 2011; 32:678.</a></li><li><a class="nounderline abstract_t">Ito T, Sato N, Yamazaki H, et al. A case of aseptic abscesses syndrome treated with corticosteroids and TNF-alpha blockade. Mod Rheumatol 2013; 23:195.</a></li><li><a class="nounderline abstract_t">Truchuelo MT, Alcántara J, Vano-Galván S, et al. Bowel-associated dermatosis-arthritis syndrome: another cutaneous manifestation of inflammatory intestinal disease. Int J Dermatol 2013; 52:1596.</a></li><li><a class="nounderline abstract_t">Chiu G, Rajapakse CN. Cutaneous polyarteritis nodosa and ulcerative colitis. J Rheumatol 1991; 18:769.</a></li><li><a class="nounderline abstract_t">Akbulut S, Ozaslan E, Topal F, et al. Ulcerative colitis presenting as leukocytoclastic vasculitis of skin. World J Gastroenterol 2008; 14:2448.</a></li><li><a class="nounderline abstract_t">Burgdorf W. Cutaneous manifestations of Crohn's disease. J Am Acad Dermatol 1981; 5:689.</a></li><li><a class="nounderline abstract_t">Tweedie JH, McCann BG. Metastatic Crohn's disease of thigh and forearm. Gut 1984; 25:213.</a></li><li><a class="nounderline abstract_t">Abide JM. Metastatic Crohn disease: clearance with metronidazole. J Am Acad Dermatol 2011; 64:448.</a></li><li><a class="nounderline abstract_t">Konrad A, Seibold F. Response of cutaneous Crohn's disease to infliximab and methotrexate. Dig Liver Dis 2003; 35:351.</a></li><li><a class="nounderline abstract_t">Reddy H, Shipman AR, Wojnarowska F. Epidermolysis bullosa acquisita and inflammatory bowel disease: a review of the literature. Clin Exp Dermatol 2013; 38:225.</a></li><li><a class="nounderline abstract_t">Raab B, Fretzin DF, Bronson DM, et al. Epidermolysis bullosa acquisita and inflammatory bowel disease. JAMA 1983; 250:1746.</a></li><li><a class="nounderline abstract_t">Najarian DJ, Gottlieb AB. Connections between psoriasis and Crohn's disease. J Am Acad Dermatol 2003; 48:805.</a></li><li><a class="nounderline abstract_t">Lee FI, Bellary SV, Francis C. Increased occurrence of psoriasis in patients with Crohn's disease and their relatives. Am J Gastroenterol 1990; 85:962.</a></li><li><a class="nounderline abstract_t">Hughes S, Williams SE, Turnberg LA. Crohn's disease and psoriasis. N Engl J Med 1983; 308:101.</a></li><li><a class="nounderline abstract_t">Kappelman MD, Farkas DK, Long MD, et al. Risk of cancer in patients with inflammatory bowel diseases: a nationwide population-based cohort study with 30 years of follow-up evaluation. Clin Gastroenterol Hepatol 2014; 12:265.</a></li><li><a class="nounderline abstract_t">Singh S, Nagpal SJ, Murad MH, et al. Inflammatory bowel disease is associated with an increased risk of melanoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2014; 12:210.</a></li><li><a class="nounderline abstract_t">Long MD, Martin CF, Pipkin CA, et al. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology 2012; 143:390.</a></li><li><a class="nounderline abstract_t">Abbas AM, Almukhtar RM, Loftus EV Jr, et al. Risk of melanoma and non-melanoma skin cancer in ulcerative colitis patients treated with thiopurines: a nationwide retrospective cohort. Am J Gastroenterol 2014; 109:1781.</a></li><li><a class="nounderline abstract_t">Ariyaratnam J, Subramanian V. Association between thiopurine use and nonmelanoma skin cancers in patients with inflammatory bowel disease: a meta-analysis. Am J Gastroenterol 2014; 109:163.</a></li><li><a class="nounderline abstract_t">Petrelli EA, McKinley M, Troncale FJ. Ocular manifestations of inflammatory bowel disease. Ann Ophthalmol 1982; 14:356.</a></li><li><a class="nounderline abstract_t">Lyons JL, Rosenbaum JT. Uveitis associated with inflammatory bowel disease compared with uveitis associated with spondyloarthropathy. Arch Ophthalmol 1997; 115:61.</a></li><li><a class="nounderline abstract_t">Knox DL, Snip RC, Stark WJ. The keratopathy of Crohn's disease. Am J Ophthalmol 1980; 90:862.</a></li><li><a class="nounderline abstract_t">Schulman MF, Sugar A. Peripheral corneal infiltrates in inflammatory bowel disease. Ann Ophthalmol 1981; 13:109.</a></li><li><a class="nounderline abstract_t">Ruby AJ, Jampol LM. Crohn's disease and retinal vascular disease. Am J Ophthalmol 1990; 110:349.</a></li><li><a class="nounderline abstract_t">Kaneko E, Nawano M, Honda N, et al. Ulcerative colitis complicated by idiopathic central serous chorioretinopathy with bullous retinal detachment. Dig Dis Sci 1985; 30:896.</a></li></ol></div><div id="topicVersionRevision">Topic 4064 Version 34.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11316157" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15290913" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Autoimmune disorders and extraintestinal manifestations in first-degree familial and sporadic inflammatory bowel disease: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37042969" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Prevalence of Extraintestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20808297" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/957999" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The extra-intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15168814" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Ocular manifestations of inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2052301" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Ocular inflammation in Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1688539" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A shared and unique epitope(s) on human colon, skin, and biliary epithelium detected by a monoclonal antibody.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12198697" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and the role of HLA genes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18794711" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: a cohort study of 2402 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26721936" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Prevalence and Characteristics of Extra-intestinal Manifestations in a Large Cohort of Greek Patients with Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14562397" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: results of a 25-year follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3889978" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Pyoderma gangrenosum: a review of 86 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1387659" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Peristomal pyoderma gangrenosum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7399325" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Pyoderma gangrenosum and ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23914999" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Systematic review: IBD-associated pyoderma gangrenosum in the biologic era, the response to therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31290938" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Association of Hidradenitis Suppurativa With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25952308" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Hidradenitis Suppurativa in Patients With Inflammatory Bowel Disease: A Population-Based Cohort Study in Olmsted County, Minnesota.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9262983" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Sweet's syndrome: an unusual cutaneous feature of Crohn's disease or ulcerative colitis. The South West Gastroenterology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22011318" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Sweet syndrome in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21382655" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : [Aseptic abscesses syndrome].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22526827" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A case of aseptic abscesses syndrome treated with corticosteroids and TNF-alpha blockade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22640167" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Bowel-associated dermatosis-arthritis syndrome: another cutaneous manifestation of inflammatory intestinal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1678018" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Cutaneous polyarteritis nodosa and ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18416478" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Ulcerative colitis presenting as leukocytoclastic vasculitis of skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6459345" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Cutaneous manifestations of Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6693047" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Metastatic Crohn's disease of thigh and forearm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21238840" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Metastatic Crohn disease: clearance with metronidazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12846408" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Response of cutaneous Crohn's disease to infliximab and methotrexate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23517353" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Epidermolysis bullosa acquisita and inflammatory bowel disease: a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6887488" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Epidermolysis bullosa acquisita and inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12789169" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Connections between psoriasis and Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2375323" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Increased occurrence of psoriasis in patients with Crohn's disease and their relatives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6847931" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Crohn's disease and psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23602821" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Risk of cancer in patients with inflammatory bowel diseases: a nationwide population-based cohort study with 30 years of follow-up evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23644389" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Inflammatory bowel disease is associated with an increased risk of melanoma: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22584081" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25244964" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Risk of melanoma and non-melanoma skin cancer in ulcerative colitis patients treated with thiopurines: a nationwide retrospective cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24419479" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Association between thiopurine use and nonmelanoma skin cancers in patients with inflammatory bowel disease: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6125121" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Ocular manifestations of inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9006426" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Uveitis associated with inflammatory bowel disease compared with uveitis associated with spondyloarthropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7446674" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The keratopathy of Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7247152" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Peripheral corneal infiltrates in inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2220968" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Crohn's disease and retinal vascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4040844" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Ulcerative colitis complicated by idiopathic central serous chorioretinopathy with bullous retinal detachment.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
